LT4218804T - Miostatino inhibitorių panaudojimas ir kompleksinės terapijos - Google Patents

Miostatino inhibitorių panaudojimas ir kompleksinės terapijos

Info

Publication number
LT4218804T
LT4218804T LTEP23157280.1T LT23157280T LT4218804T LT 4218804 T LT4218804 T LT 4218804T LT 23157280 T LT23157280 T LT 23157280T LT 4218804 T LT4218804 T LT 4218804T
Authority
LT
Lithuania
Prior art keywords
combination therapies
myostatin inhibitors
myostatin
inhibitors
therapies
Prior art date
Application number
LTEP23157280.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Kimberly LONG
Adriana Donovan
Yung CHYUNG
Michelle STRAUB
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59093642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4218804(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of LT4218804T publication Critical patent/LT4218804T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
LTEP23157280.1T 2016-06-13 2017-06-13 Miostatino inhibitorių panaudojimas ir kompleksinės terapijos LT4218804T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662349596P 2016-06-13 2016-06-13
US201762470157P 2017-03-10 2017-03-10
US201762486934P 2017-04-18 2017-04-18
US201762511702P 2017-05-26 2017-05-26
US201762512254P 2017-05-30 2017-05-30

Publications (1)

Publication Number Publication Date
LT4218804T true LT4218804T (lt) 2026-03-25

Family

ID=59093642

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP23157280.1T LT4218804T (lt) 2016-06-13 2017-06-13 Miostatino inhibitorių panaudojimas ir kompleksinės terapijos
LTEP17732001.7T LT3368069T (lt) 2016-06-13 2017-06-13 Miostatino inhibitorių naudojimas, ir kombinuotas gydymas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17732001.7T LT3368069T (lt) 2016-06-13 2017-06-13 Miostatino inhibitorių naudojimas, ir kombinuotas gydymas

Country Status (22)

Country Link
US (2) US10946036B2 (https=)
EP (3) EP3368069B1 (https=)
JP (5) JP6823167B2 (https=)
KR (5) KR20230028813A (https=)
AU (4) AU2017283546C1 (https=)
CL (1) CL2018003588A1 (https=)
CY (1) CY1123678T1 (https=)
DK (2) DK4218804T3 (https=)
ES (1) ES2830440T3 (https=)
FI (1) FI4218804T3 (https=)
HR (2) HRP20260160T1 (https=)
HU (1) HUE051480T2 (https=)
IL (3) IL301468A (https=)
LT (2) LT4218804T (https=)
MY (2) MY185614A (https=)
NZ (3) NZ789269A (https=)
PE (1) PE20190205A1 (https=)
PT (1) PT3368069T (https=)
RS (1) RS61090B1 (https=)
SI (2) SI3368069T1 (https=)
SM (1) SMT202000598T1 (https=)
WO (1) WO2017218592A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
KR102376582B1 (ko) * 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP4218817A3 (en) * 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018187209A1 (en) * 2017-04-03 2018-10-11 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019170930A1 (es) * 2018-03-09 2019-09-12 Universitat De Lleida Tratamiento para la atrofia muscular espinal
WO2019204369A1 (en) * 2018-04-17 2019-10-24 Applied Stemcell, Inc. Compositions and methods for treating spinal muscular atrophy
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113993452A (zh) * 2019-06-19 2022-01-28 豪夫迈·罗氏有限公司 数字生物标志物
JP2022537266A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
AU2021369471A1 (en) 2020-10-26 2023-06-15 Scholar Rock, Inc. Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
CA3221555A1 (en) 2021-06-23 2022-12-29 Kimberly LONG A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023057404A1 (en) * 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
DK4518970T3 (da) * 2022-05-04 2026-04-07 Scholar Rock Inc Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2026008041A1 (zh) * 2024-07-04 2026-01-08 江苏恒瑞医药股份有限公司 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2288900T3 (es) 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
MXPA05002968A (es) 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1699820A2 (en) 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008500373A (ja) 2004-05-27 2008-01-10 アクセルロン ファーマ インコーポレーテッド ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
EP2769731A1 (en) 2007-02-23 2014-08-27 The Trustees of Columbia University in the City of New York Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
ATE542876T1 (de) 2007-03-30 2012-02-15 Merck Patent Gmbh Doppelbrechungsschicht mit negativer optischer dispersion
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
WO2008150530A2 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JP5841845B2 (ja) 2009-02-24 2016-01-13 ソーク・インステチュート・フォー・バイオロジカル・スタディーズＳａｌｋ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｌｏｇｉｃａｌ Ｓｔｕｄｉｅｓ ＴＧＦ−βスーパーファミリーのデザイナーリガンド
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
MX380973B (es) * 2013-05-01 2025-03-12 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR20170135967A (ko) * 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Also Published As

Publication number Publication date
EP3368069B1 (en) 2020-08-05
AU2021261907B2 (en) 2024-06-06
EP3785728A2 (en) 2021-03-03
JP2023164920A (ja) 2023-11-14
PE20190205A1 (es) 2019-02-07
SI4218804T1 (sl) 2026-03-31
ES2830440T3 (es) 2021-06-03
EP4218804A3 (en) 2023-09-13
NZ789250A (en) 2026-01-30
SMT202000598T1 (it) 2021-01-05
EP3785728A3 (en) 2021-04-28
EP4218804A2 (en) 2023-08-02
KR20210082548A (ko) 2021-07-05
KR20230169484A (ko) 2023-12-15
CL2018003588A1 (es) 2019-03-01
US20210283166A1 (en) 2021-09-16
IL301468A (en) 2023-05-01
NZ748917A (en) 2024-04-26
EP3368069A1 (en) 2018-09-05
HUE051480T2 (hu) 2021-03-01
CY1123678T1 (el) 2022-03-24
NZ789268A (en) 2026-01-30
AU2017283546A1 (en) 2018-12-20
JP6823167B2 (ja) 2021-01-27
EP4218804B1 (en) 2026-01-21
KR20260028184A (ko) 2026-03-03
JP2022101593A (ja) 2022-07-06
HRP20201764T1 (hr) 2020-12-25
DK4218804T3 (da) 2026-02-09
LT3368069T (lt) 2020-12-10
MY199499A (en) 2023-11-01
AU2017283546C1 (en) 2020-11-19
AU2021261907A1 (en) 2021-12-02
HRP20260160T1 (hr) 2026-03-27
AU2017283546B2 (en) 2020-05-21
KR20190017933A (ko) 2019-02-20
US10946036B2 (en) 2021-03-16
PT3368069T (pt) 2020-11-11
RS61090B1 (sr) 2020-12-31
FI4218804T3 (fi) 2026-03-11
JP7344337B2 (ja) 2023-09-13
DK3368069T3 (da) 2020-11-02
MY185614A (en) 2021-05-25
US20190255093A1 (en) 2019-08-22
IL326484A (en) 2026-04-01
AU2020210134A1 (en) 2020-08-13
AU2020210134B2 (en) 2021-11-04
IL263510A (en) 2019-01-31
JP2025183233A (ja) 2025-12-16
WO2017218592A1 (en) 2017-12-21
JP7161554B2 (ja) 2022-10-26
KR20230028813A (ko) 2023-03-02
NZ789269A (en) 2026-01-30
AU2024203412A1 (en) 2024-06-27
JP2019523295A (ja) 2019-08-22
SI3368069T1 (sl) 2021-03-31
KR102271635B1 (ko) 2021-07-06
JP2021063107A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
IL326484A (en) Use of myostatin inhibitors and combination therapies
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL267291B (en) Actonucleotidase inhibitors and methods of using them
IL250415B (en) Antibodies against pd-l and methods of using them
ZA201605639B (en) Hppd variants and methods of use
GB2539350B (en) Amyloid targeting agents and methods of using the same
IL274504A (en) 2ACSS inhibitors and methods of their use
GB201421847D0 (en) Dispensers and methods of use thereof
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
PT3089971T (pt) Compostos e métodos de utilização
IL282482A (en) Variants of protoxin-II and methods of use
ZA201606243B (en) Hppd variants and methods of use
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
HUE059778T2 (hu) URAT1-inhibitor és alkalmazása
GB201417048D0 (en) Occupancy-control device and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
IL267238A (en) The paranase inhibitors and their use
ES2856150T5 (en) Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases
GB2562984B (en) Hydrate inhibitors and methods of use
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
PT3519025T (pt) Dispositivo de administração
IL267243A (en) The paranase inhibitors and their use
GB201509977D0 (en) Dispensers and methods of use thereof
GB201403697D0 (en) Compounds and methods of use